IP Library Granted Patent US 8,362,267
Granted Patent B2
US 8,362,267 · App. 12/934,521 · Granted Jan 29, 2013

Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same

Inventors: Nam-Song Choi (Cheonan-si, KR); Young-Hoon Kim (Cheonan-si, KR); Jae-Kwang Lee (Cheonan-si, KR); Hee-Ryong Kang (Cheonan-si, KR); Ho-Jin Choi (Cheonan-si, KR); Seung-Kee Moon (Cheonan-si, KR); Soo-Jin Kim (Cheonan-si, KR); Gyu-Tae Park (Cheonan-si, KR); Byeong-Hoon Han (Cheonan-si, KR); Dal-Hyun Kim (Cheonan-si, KR); Jae-Hoon Choi (Cheonan-si, KR); Sung-Sook Lee (Cheonan-si, KR); Soon-Kil Ahn (Cheonan-si, KR); Kyung-Joo Lee (Cheonan-si, KR); Su-Yeal Bae (Cheonan-si, KR)
Assignee: Chong Kun Dang Pharmaceutical Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,362,267
App. No.
12/934,521
Granted
Jan 29, 2013
Kind
B2
Abstract

Disclosed are a novel thiazole-containing benzophenone derivative represented by formula 1, and an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof and a solvate thereof, a pharmaceutical composition comprising the derivative, a use of the derivative as therapeutic agent and a method for preparing the derivative. The benzophenone thiazole derivatives inhibit formation of microtubules and eliminate actively proliferating cells of malignant tumors to control general cell proliferation. In formula 1, R, R 1 and R 2 are defined as above.

Claims (19)

1. A compound represented by formula (1) below or a stereoisomer thereof, and a pharmaceutically acceptable salt thereof:

wherein

R 1 and R 2 are each independently hydrogen or methyl; and

R is joined with R 1 or R 2 to form a 5-membered ring or R is selected from the group consisting of hydrogen, methyl, ethyl,

2. The compound according to claim 1 selected from the group consisting of:

N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-aminoacetamide;

(S)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide;

(S)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-phenylpropanamide;

N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-(dimethylamino)acetamide;

(S)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)pyrolidine-2-carboxamide;

(S)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-4-methylpentanamide;

(S)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-cyclohexylpropanamide;

N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide; and

(R)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide.

3. The compound according to claim 1 , wherein the compound is (S)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide.

4. The compound according to claim 1 , wherein the compound is (S)—N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-phenylpropanamide.

5. A pharmaceutical composition, comprising the compound according to claim 1 as an active ingredient, and a pharmaceutically acceptable excipient or carrier.

6. A method for preparing a compound represented by formula (6), comprising reacting a (Compound 516), [{4-(2-aminothiazol-4-yl)-2-(1H-1,2,4-triazol-1-yl)phenyl}(3,4,5-trimethoxyphenyl)methanone], with a compound represented by formula (3) or formula (5):

wherein R 1 ′ is Fmoc(9-fluorenylmethoxycarbonyl) group or CH 3 ; R 2 is H or CH 3 ; and R is joined with R 2 to form a 5-membered ring or R is selected from the group consisting of hydrogen, methyl, ethyl,

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2014
From: CHONG KUN DANG HOLDINGS CORP.
To: CHONG KUN DANG PHARMACEUTICAL CORP.
Reel/Frame 033620/0229 →
CHANGE OF NAME Recorded Aug 20, 2014
From: CHONG KUN DANG PHARMACEUTICAL CORP.
To: CHONG KUN DANG HOLDINGS CORP.
Reel/Frame 033577/0682 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2010
From: CHOI, NAM-SONG; KIM, YOUNG-HOON; LEE, JAE-KWANG; KANG, HEE-RYONG; CHOI, HO-JIN; MOON, SEUNG-KEE; KIM, SOO-JIN; PARK, GYU-TAE; HAN, BYEONG-HOON; KIM, DAL-HYUN; CHOI, JAE-HOON; LEE, SUNG-SOOK; AHN, SOON-KIL; LEE, KYUNG-JOO; BAE, SU-YEAL
To: CHONG KUN DANG PHARMACEUTICAL CORP.
Reel/Frame 025042/0574 →
Priority Claims (1)
KR 10-2008-0027820 · Mar 26, 2008 · national
Continuity (1)
Related Publication 20110021582A1 · Jan 27, 2011